Structured evidence table for Berberine Pcos Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Berberine Pcos Randomized Trial | It is clinically defined by at least two of the following: (1) oligo-anovulation, (2) hyperandrogenism (clinical or biochemical), and (3) polycystic ovary morphology or increased anti-Müllerian hormone levels []. | 3 | Wu Xinhong (2026) | Precision Targeted Therapy for PCOS: Emerging Drugs, Translational Challenges, and Future Opportunities |
| Berberine Pcos Randomized Trial | Patients face a 4- to 10-fold increased risk of Type 2 Diabetes Mellitus (T2DM), alongside heightened susceptibility to cardiovascular disease, endometrial cancer and psychological morbidities such as anxiety and depression [,,]. | 3 | Wu Xinhong (2026) | Precision Targeted Therapy for PCOS: Emerging Drugs, Translational Challenges, and Future Opportunities |
| Berberine Pcos Randomized Trial | 13 14 15 16 Furthermore, their use requires a careful risk-benefit analysis regarding the additive risk of venous thromboembolism (VTE), particularly in patients with co-existing obesity or advanced reproductive age, who already harbor a baseline thrombotic risk due to PCOS itself [,,,]. | 3 | Wu Xinhong (2026) | Precision Targeted Therapy for PCOS: Emerging Drugs, Translational Challenges, and Future Opportunities |
| Berberine Pcos Randomized Trial | 1 2 3 4 5 6 7 Polycystic ovary syndrome (PCOS) represents the most prevalent endocrine-metabolic disorder in women of reproductive age, affecting 6% to 21% of the global population [,,]. | 3 | Wu Xinhong (2026) | Precision Targeted Therapy for PCOS: Emerging Drugs, Translational Challenges, and Future Opportunities |
| Berberine Pcos Randomized Trial | Objective and rationale This narrative review critically evaluates current evidence on lifestyle-based and adjunct therapeutic strategies in PCOS management, with emphasis on dietary interventions, physical activity, nutraceuticals, and traditional remedies, focusing on their potential to modulate metabolic, endocrine, and inflammatory pathways alongside conventional clinical treatments. | 4 | Nandagopal PB (2026) | Integrating evidence-based lifestyle and adjunct therapies for long-term management of polycystic ovary syndrome: mechanistic insights and clinical implications. |
| Berberine Pcos Randomized Trial | Key findings Emerging evidence highlights the multifaceted role of lifestyle and adjunct interventions in improving the clinical outcomes in PCOS. | 4 | Nandagopal PB (2026) | Integrating evidence-based lifestyle and adjunct therapies for long-term management of polycystic ovary syndrome: mechanistic insights and clinical implications. |
| Berberine Pcos Randomized Trial | Dietary approaches, including Mediterranean, low-glycemic index, ketogenic, and anti-inflammatory diets, are associated with improvements in metabolic parameters and insulin sensitivity. | 4 | Nandagopal PB (2026) | Integrating evidence-based lifestyle and adjunct therapies for long-term management of polycystic ovary syndrome: mechanistic insights and clinical implications. |
| Berberine Pcos Randomized Trial | Background Polycystic ovary syndrome (PCOS) is a complex multisystem disorder affecting 6%-13% of reproductive-aged women, characterized by hormonal and metabolic dysregulation. | 4 | Nandagopal PB (2026) | Integrating evidence-based lifestyle and adjunct therapies for long-term management of polycystic ovary syndrome: mechanistic insights and clinical implications. |
Source documents